Cargando...
Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
Rationale: Two antifibrotic medications, nintedanib and pirfenidone, have been approved for the treatment of idiopathic pulmonary fibrosis (IPF) in the United States. Few data have been published on the use of these medications in clinical practice. Objectives: To investigate patterns of use of anti...
Gardado en:
| Publicado en: | Ann Am Thorac Soc |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Thoracic Society
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7640723/ https://ncbi.nlm.nih.gov/pubmed/32574517 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1513/AnnalsATS.201912-880OC |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|